Targeting a protein to improve treatment for Acute Myeloid Leukemia
Targeting NAMPT in Acute Myeloid Leukemia
['FUNDING_R01'] · OHIO STATE UNIVERSITY · NIH-10459455
This study is looking at how blocking a protein called NAMPT might help treat Acute Myeloid Leukemia (AML) by making it harder for the cancer cells to survive and grow, and it's designed for all AML patients, no matter their specific genetic makeup.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-10459455 on ClinicalTrials.gov |
What this research studies
This research focuses on Acute Myeloid Leukemia (AML), a complex blood cancer characterized by the rapid growth of abnormal cells. The study investigates the role of a protein called NAMPT, which is crucial for the production of NAD+, a molecule that helps cancer cells survive and grow. By inhibiting NAMPT, the research aims to disrupt the metabolism of these cancer cells, potentially leading to better treatment outcomes. The approach is designed to be applicable to a wide range of AML patients, regardless of specific genetic mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Acute Myeloid Leukemia, particularly those who have not responded well to existing therapies.
Not a fit: Patients with other types of leukemia or those who are not diagnosed with any form of blood cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with Acute Myeloid Leukemia, potentially reducing relapse rates and improving survival.
How similar studies have performed: While some agents targeting NAMPT have been tested in early clinical trials, this approach is still considered novel and has not yet been widely validated.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LAPALOMBELLA, ROSA — OHIO STATE UNIVERSITY
- Study coordinator: LAPALOMBELLA, ROSA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.